TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Trump Picks Wall Street Attorney Jay Clayton for Top SEC Post
STOCKS

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

PRESS RELEASES

OncoSec Announces First Subjects Dosed In Phase 1 Trial Of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) With An Enhanced SARS-CoV-2 Spike Protein

PRESS RELEASES

OncoSec Medical Closes $42.0 Million Public Offering Of Common Stock

PRESS RELEASES

OncoSec Medical Announces Pricing Of $42.0 Million Public Offering Of Common Stock

PRESS RELEASES

OncoSec Medical Announces Proposed Public Offering Of Common Stock

PRESS RELEASES

Sirtex Medical Announces Collaboration Update With OncoSec Medical

PRESS RELEASES

OncoSec Enters Into Option Agreement With Sirtex Medical To Co-Promote TAVO™

PRESS RELEASES

OncoSec Announces First Patient Dosed In Phase 2 Trial Of TAVO™ Plus OPDIVO® As Neoadjuvant Therapy For Melanoma

PRESS RELEASES

OncoSec Strengthens IP Portfolio With Allowance Of Two European Patent Applications Covering TAVO™ And Its Gene Electrotransfer Technology

PRESS RELEASES

OncoSec Announces Publication In International Journal Of Surgery Case Reports

PRESS RELEASES

OncoSec Announces Exclusive License Agreement For Cliniporator® Gene Electrotransfer Platform Developed By IGEA Clinical Biophysics

PRESS RELEASES

OncoSec Provides Highlights From Analyst & Investor Day And SITC 2020 And Announces KEYNOTE-695 Reaches Full Enrollment

PRESS RELEASES

OncoSec Announces Positive Interim Data From KEYNOTE-695 Trial In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma At SITC 2020

PRESS RELEASES

OncoSec Hosting An Investor And Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

PRESS RELEASES

OncoSec To Present Positive Interim Data From KEYNOTE-695 Trial In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma At SITC 2020

PRESS RELEASES

OncoSec Announces FDA Clearance Of IND Application For Initiation Of Phase 1 Clinical Trial Of Its CORVax12 Vaccine Candidate For COVID-19

PRESS RELEASES

OncoSec To Present At The LD 500 Virtual Conference On September 2, 2020

PRESS RELEASES

OncoSec Medical Incorporated Announces Pricing Of Public Offering

PRESS RELEASES

OncoSec Medical Incorporated Announces Proposed Public Offering Of Common Stock

PRESS RELEASES

OncoSec To Present At The BTIG Virtual Biotechnology Conference 2020 On Tuesday, August 11, 2020

PRESS RELEASES

OncoSec Appoints Kellie Malloy Foerter As Chief Operating Officer

PRESS RELEASES

OncoSec's Novel COVID-19 Vaccine Candidate Featured In 'Straight Talk' Program By NBC TV In Portland, Oregon

PRESS RELEASES

OncoSec To Be Featured In "Grand Rounds: A Webinar In Biotech And Specialty Pharma," Webinar Hosted By Alliance Global Partners

PRESS RELEASES

OncoSec Set To Join Russel Microcap® Index

PRESS RELEASES

OncoSec Presents Two Late-Breaking Abstracts On TAVO-PLUS At The American Association For Cancer Research (AACR) Virtual Annual Meeting II